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Abstract
Background: The α7 nicotinic acetylcholine receptor increasingly has been implicated in normal brain physiology, as well as in 
neuropsychiatric disorders. The highly cortical distribution of α7 nicotinic acetylcholine receptor suggests a role in cognition.
Methods: We expanded the first-in-human PET imaging of α7 nicotinic acetylcholine receptor with [18F]ASEM from 5 to 21 
healthy nonsmoking volunteers and added a feasibility study in 6 male patients with schizophrenia. Study aims included: 
(1) confirmation of test-retest reproducibility of [18F]ASEM binding, (2) demonstration of specificity by competition with 
DMXB-A, an α7 nicotinic acetylcholine receptor partial agonist, (3) estimation of [18F]ASEM binding potentials and α7 nicotinic 
acetylcholine receptor density in vivo in humans, and (4) demonstrating the feasibility of studying α7 nicotinic acetylcholine 
receptor as a target for schizophrenia.
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Results: Test-retest PET confirmed reproducibility (>90%) (variability ≤7%) of [18F]ASEM volume of distribution (VT) estimates 
in healthy volunteers. Repeated sessions of PET in 5 healthy subjects included baseline and effect of inhibition after oral 
administration of 150 mg DMXB-A. From reduction of binding potentials, we estimated the dose-dependent occupancy of α7 
nicotinic acetylcholine receptor by DMXB-A at 17% to 49% for plasma concentrations at 60 to 200 nM DMXB-A. In agreement 
with evidence postmortem, α7 nicotinic acetylcholine receptor density averaged 0.67 to 0.82 nM and inhibitor affinity constant 
averaged 170 to 385 nM. Median VT in a feasibility study of 6 patients with schizophrenia was lower than in healthy volunteers 
in cingulate cortex, frontal cortex, and hippocampus (P = 0.02, corrected for multiple comparions, Mann–Whitney test).
Conclusions: The current results confirm the reproducibility of [18F]ASEM VT estimates and the specificity of the tracer for 
α7 nicotinic acetylcholine receptor. Preliminary findings from our feasibility study of [18F]ASEM binding in patients with 
schizophrenia are suggestive and provide guidance for future studies with more subjects.
Keywords: PET imaging, nicotinic acetylcholine receptors, schizophrenia
Introduction
As ligand-gated excitatory cation channels, nicotinic acetyl-
choline receptors (nAChRs) in central nervous system (CNS) are 
fundamental to physiology (Lukas et al., 1999). The 2 nicotinic 
receptor subtypes, α4β2 and α7, predominate in CNS among 
many other nAChR subtypes (Lukas et  al., 1999; Gotti and 
Clementi, 2004). Nicotine binds with high affinity to α4β2-nAChR 
(KI ~ 1 nM; Anderson and Arneric, 1994) and with a much lower 
affinity to α7-nAChR (KI ~ 6000–14 000 nM; Davies et al., 1999).
The α7-nAChR subtype is associated with the pathophysi-
ology of specific CNS diseases, including schizophrenia, drug 
addiction, depression, anxiety, and multiple neurodegen-
erative disorders (Verbois et  al., 2000, 2002; Woodruff-Pak and 
Gould, 2002; Albuquerque et  al., 2009; D’Hoedt and Bertrand, 
2009; Philip et al., 2010; Hoffmeister et al., 2011; Ishikawa and 
Hashimoto, 2011; Parri et al., 2011) and therefore is an import-
ant target of drug discovery. Multiple postmortem studies have 
shown reduced α7 receptors in brain samples from patients 
with schizophrenia, suggesting a role of α7 in schizophrenia (see 
review by Thomsen et  al., 2010). In autoradiography of brains 
from patients with schizophrenia, reductions of α-[125I] BTX 
binding to α7 were demonstrated in hippocampus, anterior cin-
gulate cortex, and thalamic reticular nucleus (Freedman et al., 
1995) but not in orbitofrontal or temporal lobes (Court et  al., 
1999; Marutle et al., 2001).
The α7-nAChR has emerged as a potential therapeutic 
target for treatment of schizophrenia (Wallace et  al., 2011; 
AhnAllen, 2012; Geerts, 2012; Wallace and Bertrand, 2013; 
Young and Geyer, 2013a; Freedman, 2014b; Beinat et al., 2015). 
In animals, stimulation of α7 is procognitive (Young and Geyer, 
2013a; Potasiewicz et  al., 2017). In clinical trials with select-
ive α7 agonists, activation of the receptor improved cognitive 
performance in patients with schizophrenia. Selected drugs 
(DMXB-A, also known as GTS-21, TC-5619, and EVP-6124) show 
some degree of cognitive improvement in trials of patients with 
schizophrenia, although none has yet proceeded to late phase 
or FDA approval. A common trend is the improvement of cog-
nition with an inverted U-shaped dose–response curve, when 
increasing the dose of α7 agonist above a threshold resulted 
in loss of drug effect (Wallace and Bertrand, 2015; Lewis et al., 
2017). The latest research has revealed a new generation of 
promising α7-targeting drugs (Beinat et al., 2016).
Despite the importance of the nicotinic receptor system, 
the physiological and pharmacological roles of specific recep-
tor subtypes in CNS remain poorly understood (Philip et  al., 
2010; Ishikawa and Hashimoto, 2011; Marrero et al., 2011; Parri 
et al., 2011). Until recently, the lack of radioligands for quanti-
tative emission tomography imaging of α7-nAChR in humans 
hampered noninvasive research of this receptor system. Many 
radiotracers of interest to α7-nAChR (11C-CHIBA-1001; Toyohara 
et al., 2009), 11C-NS14492 (Ettrup et al., 2011; Magnussen et al., 
2015), and others have been tested, but most had suboptimal 
properties in PET of humans (see Gao et  al., 2013 for review). 
Here, we further tested human subjects with [18F]ASEM, the 
only α7-nAChR PET tracer available to humans with promis-
ing imaging characteristics (Gao et al., 2013b; Horti et al., 2014b; 
Horti, 2015; Coughlin et al., 2018; Hillmer et al., 2017; Wong et al., 
2017). Objectives included: (1) confirmation of test-retest repro-
ducibility of [18F]ASEM binding in brain of normal volunteers, (2) 
demonstration for the first time of specific binding and target 
engagement/occupancy in human brain of the partial agonist 
DMXB-A (GTS-21), (3) estimation for the first time of [18F]ASEM 
binding potentials and α7-nAChR receptor density (Bmax) and 
inhibitor affinity constant (KI) for human brain in vivo, and (4) a 
feasibility study of the target role of α7-nAChR in psychosis in 6 
patients with schizophrenia.
Methods
Subjects
All studies were carried out with the approval of the Johns 
Hopkins Institutional Review Board, where all subjects provided 
written informed consent. Participants were recruited via adver-
tisements within the metropolitan Baltimore region.
Twenty-one healthy, nonsmoking control subjects (13 
males and 8 females; age range: 18–52  years; means ± SD: 
32.6 ± 12.4 years) volunteered for the study. In addition to base-
line PET, 12 subjects had a second baseline PET (test-retest), and 
5 other subjects had a second PET after a single dose of DMXB-A. 
Only 8 of the 12 subjects had successful test-retest PET due to 
technical problems in either test or retest in 4 subjects. Of the 
subjects, 5 (including 2 with test-retest from a previous publi-
cation by Wong et al., 2014) were included in this study. Healthy 
volunteers had no psychotropic treatment history, were free of 
significant medical or neuropsychiatric disorder, and received 
no current medications.
To examine the feasibility of measuring α7 nAChR in 
schizophrenia, 6 patients diagnosed with schizophrenia (aged 
20–31  years; average 25.0 ± 4.3 [SD] y; all males; 1 smoker 
only) were recruited. Volunteers with schizophrenia that met 
DSM-V criteria, with stable antipsychotic medication other 
than clozapine, were referred by collaborating psychiatrists. 
Subjects underwent neuropsychiatric characterization includ-
ing Brief Psychiatric Rating (BPRS) scores. Demographic data 
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for healthy controls and subjects with schizophrenia are listed 
in Table 1A, 1B. Participants provided information of history of 
tobacco use, including number of cigarettes per day and years 
of tobacco use.
All subjects (controls and patients with schizophrenia) had 
negative urinary toxicology tests and provided CO breath sam-
ples of <4 ppm on the imaging day to confirm abstinence for at 
least 12 h from tobacco smoking for any subjects (see additional 
inclusion/exclusion criteria in Supplemental Material).
One patient with schizophrenia was tested with PET [18F]
ASEM while chronically treated with risperidone and then 
retested with PET without drug for 3 weeks (discontinued for 
clinical reasons).
To address possible effects of antipsychotics administered to 
patients, we determined biodistribution in mice treated for 5 d 
with cohorts of placebo vs risperidone, aripiprazole, or olanzap-
ine, the 3 most common drugs in the present patient population, 
at doses equivalent to doses used in humans (Reagan-Shaw et al., 
2008; Dawe et al., 2010; McOmish et al., 2012; Ning et al., 2017). 
Mice were i.v. injected with [18F]ASEM and sacrificed after 60 min 
(detailed Methods and Figure A in Supplemental Materials).
PET
All subjects underwent PET with the Siemens/CTI High-
Resolution Research Tomography (HRRT: resolution <2  mm). 
The dynamic imaging continued for 90  min with the frame 
sequences of 4 x 15  s, 4 x 30  s, 3 x 60  s, 2 x 120  s, 5 x 240  s, and 
12 x 300 s. Each subject received a radial arterial catheter for col-
lection of approximately 40 arterial blood plasma samples and 
subsequent HPLC radiometabolite detection during the 90-min 
imaging session. Arterial plasma samples were drawn as rapidly 
as possible for the first 2 min and then every minute until 10 min 
post injection, every 2 min until 20 min post injection, and at the 
times 25, 30, 45, 60, 75, and 90  min post injection. Metabolites 
were measured for the times of 2, 5, 10, 20, 30, 60, and 90 min 
post injection. (See Supplemental Material for HPLC methods.)
Each subject received 13.8 mCi ± 0.23 (SEM) [18F]ASEM synthe-
sized by the method of Gao et  al. (2013) with average specific 
activity of 56 417 Ci/mmol. There were no significant differences 
in injected radioactivity or specific activity between the controls 
and patients with schizophrenia. Tracer-free fraction in plasma 
across subjects averaged 2.79% ± 0.06 (SD) and was not signifi-
cantly different in healthy controls and patients with schizo-
phrenia (methods in Supplemental Materials).
Of the healthy volunteers, 12 were retested with [18F]ASEM 
imaging approximately 5 weeks (mean 41.2 d) after the first 
PET session, including 3 reported by Wong et al. (2014). We care-
fully reviewed the radiometabolite HPLC results and elected to 
exclude 4 subjects for technical reasons (e.g., defective capture 
columns during early development of HPLC procedures). To 
determine the target engagement (occupancy) by a receptor lig-
and and to obtain evidence of specific binding of [18F]ASEM to α7-
nAChR in humans, 5 healthy subjects additionally underwent 
a second imaging session after administration of oral 150  mg 
of the partial agonist DMXB-A, 40  min before the PET tracer 
injection. Radial arterial samples for detection of concentra-
tion DMXB-A were obtained during PET imaging at 70, 100, and 
130 min post-oral dose of DMXB-A. Concentrations of DMXB-A 
in subjects’ plasma samples were determined quantitatively by 
Table 1A. Group Demographics
Diagnosis Condition n Males Females
Age 
(mean/SD) Age (range)
Healthy controlsa Baseline 21 13 8 32.0 (12.4) 18–52
Retest 8 6 2 37.8 (11.7) 20–52
Blocking 5 3 2 22.1 (4.5) 18–28
Patients with schizophrenia Baseline 6 6 0 24.8 (3.9) 20–31
aNo healthy controls reported current or past smoking history.
Table 1B. Patients with Schizophrenia
Subject ID Age Sex Race Ethnicity
BPRS – Negative 
(M)
BPRS – Positive 
(M) Smoker Cigarettes/d Medications
01 27 M AA NH 2.25 1.25 No N/A Aripiprazole
02 31 M W NH 3 1 Yes 20 Haloperidol, 
benztropine, 
sertraline
03 22 M AA NH 2.75 2.25 No N/A Risperidone
04 25 M AA NH 2.75 1.75 No N/A Quetiapine, 
haloperidol, 
benztropine
05 20 M AA NH 1.5 1.5 No N/A Escitalopram, 
benztropine, 
aripiprazole, 
clonezapam
06 – Scan 1 24 M W NH 2.75 3.25 No N/A Risperidone, 
lorazepam
06 – Scan 2 24 M W NH 1.0 1.0 No N/A Lorazepam
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HPLC with a modification of the previously reported method 
(Kem et al., 2004). (Details in Supplemental Material.)
Menstrual phase for the women was determined by a pro-
gesterone level using levels exceeding 2 ng/mL, indicating luteal 
phase. For 2 women (one in luteal phase and one in follicular 
phase), menstrual phase was determined by self-reported men-
strual history, as progesterone samples were not available.
PET Analysis
Volumes of Interest
Volumes of interest (VOI) were selected automatically in indi-
vidual subject SPGR MRI volumes using FSL (FMRIB Software 
Library; Jenkinson et al., 2012) FIRST tool (Patenaude et al., 2011) 
for subcortical regions and Freesurfer tool (Fischl et  al., 2004) 
for cortical regions. Automated VOI were manually edited to 
suit the structures of interest, using a locally developed VOI tool 
(VOILand). Refined VOI were transferred from MRI to PET spaces 
according to MRI to PET coregistration parameters obtained 
from the co-registration module of SPM12 (Statistical Parametric 
Mapping; Ashburner and Friston, 2003). The VOI of PET space 
were applied to PET frames to obtain time-activity curves of 
regions. Head-motion correction was performed with the image 
co-registration module of SPM12.
Total volumes of distribution (VT) and test-retest variability 
were estimated for all 21 cortical VOI (Figure 1A–B). In addition, 
the full VOI set was used in the calculation of dose-depend-
ent inhibition (Figure  2) as well as for the averaged estimates 
of maximum binding capacity (Bmax; Figure  3) and inhibitor KI 
(Figure 4). For analysis of VT differences (in patients vs control 
subjects, Figure 5) and potential correlation with BPRS score (see 
Supplemental Material), we chose 3 cortical regions implicated 
in autoradiography with [125I]α-bungarotoxin ([125I]BTX) of brain 
of patients with schizophrenia postmortem, previously reported 
with significant reductions in hippocampus (~70%, Freedman 
et al., 1995), frontal cortex (40%, Guan et al., 1999), and cingulate 
cortex (54%, Marutle et al., 2001).
Kinetic Analysis
Quantification of [18F]ASEM steady-state volumes of distribu-
tion (VT) proceeded as previously published (Wong et al., 2014). 
Specifically, the plasma reference graphical analysis was used 
Figure  2. Dose-dependent inhibition with DMXB-A level. The saturation, s, 
reflects the fraction of receptor occupied by the blocking agent, DMXB-A. Each 
point on the curve represents individual measurements of the plasma level of 
DMXB-A, determined by HPLC mass spectroscopy, and the fraction of receptors 
occupied by DMXB-A, estimated by the Extended Inhibition Plot (EIP). The hori-
zontal error bars represent the SEM from 3 measurements, and the vertical error 
bars reflect the SEM from the linear analysis of the Extended Inhibition plot. 
These data were fit to the Michaelis-Menten equation, with Omax assigned to a 
value of 1; (i.e, 100% occupancy, or a saturation fraction, s = 1). This is typical for 
receptor occupancy studies with PET. However, further studies at higher plasma 
concentrations may indicate a lower maximal occupancy, due to the unique 
nature of the α7 subunit, as stated in the Discussion.
Figure 1. Estimates of VT and test-retest variability for VT. (A) Regional estimates of VT for all healthy control subjects (n = 21). (B) Test-retest variability of VT in 8 healthy 
controls. For both panels, bars show mean ± SD. Abbreviations: Am, amygdala; CN, caudate nucleus; Cb, cerebellum; Cg, cingulate; Fr, frontal lobe; Fs, fusiform gyrus; 
GP, globus pallidus; Hp, hippocampus; In, insula; LG, lingular gyrus; Oc, occipital lobe; pC, paracentral; PH, parahippocampus; Pa, parietal lobe; PS, postcentral gyrus; Pc, 
precentral gyrus; Pr, precuneus; Pu, putamen; Tp, temporal lobe; Th, thalamus; vS, ventral striatum.
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Figure 3. Regional binding potentials (BPND). The analysis using the Extended Inhibition Plot (EIP) revealed that the BPND decreased significantly in response to compe-
tition with DMXB-A by 31% in average compared with baseline. Each line on the graphs of 6 representative regions of the original 21 regions displays the estimates of 
BPND in individual subjects at baseline and inhibition condition.
Figure 4. Bmax estimates. Average Bmax across all regions (21 VOIs total) were computed from the known BPND estimates, the plasma concentration of DMXB-A and the 
receptor affinity, KD, which was calculated as 0.35 nM based on known values from 
125I α–bungarotoxin in vitro studies. The analysis reveals that the average Bmax across 
all regions ranged from 0.76 to 0.96 nM in the 5 subjects, and the Ki ranged from 170 to 385 nM.
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to obtain regional VT values that served as primary outcome 
variable for test-retests and analyses with age, sex, and neuro-
psychiatric testing as well as serving as secondary outcome 
variable for estimates of the reference volume of nondisplace-
able bound radioligand (VND), competitor saturation of receptors 
(s), binding potentials (BPND), and Bmax. We completed Bmax and 
affinity (IC50, KI) estimates of α7-nAChR in 3 steps in 5 subjects 
by means of DMXB-A inhibition.
We estimated the occupancy of the partial agonist inhibitor by 
means of estimates of the radioligand’s volume of nondisplace-
able distributed tracer in the baseline (VND), obtained from baboon 
brain in vivo (Horti et al., 2014), using the conventional Inhibition 
Plot (IP) of Gjedde and Wong (2000). We compared the value of VND 
obtained from the decline of the magnitude of the total volume of 
VT in in the presence of 2 different concentrations of SR180711, of 
which we used the value associated with the lower dose to avoid 
affecting the value of VND by changes of protein binding in brain 
tissue or circulation or both (see supplemental Figure B illustrat-
ing the VND determination in baboon brain).
Applied to regional VT, the IP yielded reference volumes (VND) 
and degrees of saturation (s), according to the equation (Phan 
et al., 2017), 
 V s V sVT(i) T b ND= -( ) +1 ( ) , (1)
where VT (b) symbolizes the volume of distribution at baseline 
and VT (i) the volume at inhibition in presence of DMXB-A that 
competes with the radiotracer for binding to the binding site. 
According to Equation (1), when the regional estimates of VT in 
the inhibition condition were plotted as functions of the esti-
mates in the baseline condition, the solution yielded the refer-
ence volume, VND, and the fraction of receptors occupied by the 
competitive drug, s.
The initial analysis revealed VT estimates before and after 
DMXB-A inhibition of similar magnitudes, compensating for 
values of VND that may be different in the inhibition and base-
line conditions. To resolve this issue, we applied the Extended 
IP equation (EIP; Phan et  al., 2017) that relates the radioli-
gand distribution volumes at inhibition and baseline as fol-
lows: 
 V s
V
V
V sVT i
ND(i)
ND(b)
T(b) ND(i)( ) = -( )
é
ë
êêê
ù
û
úúú
+1 , (2)
where values of VND at baseline and inhibition are different, 
denoted VND (b) and VND (b) at baseline and inhibition, respect-
ively. The EIP yielded the value of VND in the inhibition condi-
tion (VND(i)), when the true reference volume at baseline (VND(b)) is 
known such that estimates yielded by EIP depend on a measure 
of the magnitude of the reference volume.
Volumes of distribution (VT and VND) yielded BPND. We esti-
mated the BPND of 5 subjects with DMXB-A inhibition in the 
baseline and at inhibition, using the values of VT(b) and VND(b) in 
the baseline condition and the values of VT(i) and VND(i) at inhib-
ition obtained by means of Equation (2), in the unblocked and 
DMXB-A inhibited states, with the equation 
 BP
V
V
V
VND(b)
T(b)
ND(b)
ND(i)
T(i)
ND(i)
and BP= - = -1 1 , (3)
where the BPND (b) and BPND(i) terms symbolize the BPND at baseline 
and inhibition, respectively.
The BPND and inhibitor concentrations (Ci) yielded the Bmax 
and KI (IC50) estimates of the receptor and inhibitor, respect-
ively. We completed Bmax and affinity of the competitor (IC50, KI) 
calculation of α7-nAChR in 5 subjects by means of DMXB-A 
inhibition using the values of BPND of baseline and inhibition 
that led to the novel (never previously published) in vivo esti-
mate of the magnitude of the Bmax and KI of nAChR in humans, 
using the equation 
 BP DMXB-AND
max
d
I
=
+ [ ]
æ
è
çççç
ö
ø
÷÷÷÷
B
K
K
1
 (4)
where the Bmax is determined relative to the affinity of the radio-
ligand to the receptor, Kd, with known values of the inhibitor 
concentration [DMXB-A] and the receptor’s affinity for inhibitor, 
KI. For this calculation, we used a calculated value of ASEM Kd of 
0.35 nM (established from prior measure of KI of 0.4 nM for [
123I] 
bungarotoxin) (Xiao Y et al., 2009).
Schizophrenia
As a feasibility study, we compared 6 patients with schizophre-
nia to a subset of 15 healthy volunteers matched for age, within 
3 specific brain regions: hippocampus and cingulate and frontal 
cortices. In this subset, the mean age of healthy volunteers was 
Figure 5. Distribution of VT in healthy patients and controls. Boxplots of the distribution of VT in healthy controls (HC) and patients with schizophrenia (SCZ) in cingu-
late cortex (Cg), hippocampus (Hp), and frontal cortex (Fr). The single points above the limits of the boxplot are outliers.
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23 ± 4 (SD) y, range 18 to 30, and for patients with schizophrenia 
the mean age was 24 ± 4 (SD) y, range 20–31 y.
Results
Regional VT
Regional estimates of VT in selected regions are shown in 
Figure 1A. We tested the test-retest variability of the VT estimates 
in 8 healthy subjects, 6 males (average age 41)  and 2 females 
(average age 24 y). Across all cortical and subcortical VOIs, the 
average test-retest variability was 7.8% ± 0.6% (SD, see Figure 1B), 
ranging from 6.5% to 8.9% (repeatability of >90%).
Receptor Kinetics
The reanalysis of inhibition of [18F]ASEM binding in baboon 
(Horti et al., 2014) yielded the VT of nondisplaceable tracer accu-
mulation at baseline (VND(b)), In the baboon, the VT of [
18F]ASEM 
declined markedly in response to blocking with the high affin-
ity inhibitor SSR180711. The reference volume VND assessed by 
means of the standard IP is presented in Figure 2, with the esti-
mate of VND (b) of 5.4 ml/cm
3 at the lower dose of the SR180711. 
We note that the magnitude of VND is a property of the tracer 
[18F]ASEM that we assume to be representative of mammalian 
brains in general.
We used the value of VND of 5.4  mL/cm
3 as the value of 
VND (b) in the EIP, required when VT values failed to yield evi-
dence of inhibition of radioligand binding by DMXB-A in 
human brain. In 5 subjects, the value of VND(b) yielded estimates 
of saturation (s) and inhibition reference volume (VND(i)), as 
shown in Figure 2 of the individual estimates of s as function 
of the concentration of DMXB-A in arterial plasma, confirming 
the dose-dependent inhibition exerted by DMXB-A. Estimates 
of regional BPND declined significantly in 6 of the 21 representa-
tive regions after blocking with DMXB-A, as shown in Figure 3. 
The average values for all 21 regions of Bmax and average values 
of the receptor’s KI to DMXB-A ranged from 0.67 to 0.82 nM for 
Bmax and from 170 to 385  nM for KI, as presented in Figure  4. 
Regarding the choice of the VND (b), the standard error of the VND (b) 
estimate in baboon of 2.7  mL/cm3 corresponded to ranges of 
human Bmax estimates of 0.4 to 1.9 nM and DMXB-A K estimates 
of 138 to 363 nM.
Menstrual Cycle
The menstrual cycle phase (luteal vs follicular) was determined 
for the 8 healthy control females. Estimates of VT did not differ 
significantly in relation to cycle phase. The lower ages of women 
volunteers precluded analysis of different changes of VT with 
age in men and women.
Schizophrenia
To evaluate the feasibility of studying patients with schizo-
phrenia, we compared patients with healthy control subjects. 
In the 3 preselected regions (cingulate and frontal cortices, 
hippocampus) examined for group differences between 
patients and the age-matched control subjects, the median 
VT values were lower in patients than in age-matched healthy 
volunteers (Figure  5). Potential outliers, one a control sub-
ject and one a patient, were identified (outlier points marked 
in boxplots of Figure 5). Using the Mann-Whitney U-test, we 
tested for significant differences in median VT values between 
control subjects and patients, before and after excluding out-
liers. The results, with corrections for multiple comparisons, 
are given in Table 2. In the cingulate cortex and hippocampus, 
the difference in VT was significant after exclusion of outli-
ers and correction for multiple comparisons (P = .02 in both 
regions).
The correlation of estimates of VT with scores of BPRS did 
not reach statistical significance, although there were positive 
trends for values in cingulate and frontal cortices in 5 subjects 
after outlier analyses (see supplementary Figure C for details).
Antipsychotic Medication
The biodistribution in mice revealed no significant effects on 
[18F]ASEM binding of aripriprizole, risperidone, or olanzapine (see 
Supplemental Materials). As described in Methods, the patient 
with schizophrenia chronically treated with risperidone had 
repeated PET after a 3-week drug-free period, imposed for clini-
cal reasons. The VT estimates did not differ by more than 7% (i.e., 
within the test-retest variability of control subjects in any brain 
region for the on- and off–risperidone comparison (Figure  1B) 
(supplementary Figure D, points labelled “on” and “off”).
Discussion
Subjects
We extended the first-in-human report of Wong et al. (2014) from 
5 to 21 healthy subjects (8 test-retest sessions, 5 sessions with 
inhibition by DMXB-A of [18F]ASEM binding, and 6 baseline ses-
sions) and added a preliminary study of 6 patients with schizo-
phrenia, with 1 patient receiving test-retest PET in the absence 
and presence of chronic risperidone medication.
Table 2. Corrected and Uncorrected P Values from VT in Controls vs Patients Results (uncorrected P values and corrected by different methods) 
of Mann-Whitney tests for VT in Healthy Controls vs Patients with Schizophrenia 
Region Uncorrected P value Adjusted (Horchberg) Adjusted (Bonferroni) Adjusted (Simes)
All Data
 Cg .056 .159 .167 .118
 Fr .171 .172 .515 .172
 Hp .079 .159 .238 .119
With outliers removed
 Cg .009 .028 .028 .025
 Fr .058 .058 .173 .058
 Hp .017 .033 .05 .025
Adjusted P values were obtained by the STATA package qqvalue using 3 different methods of adjustment (Newson, 2010; specific methods are Horcberg, 1998, stand-
ard Bonferroni correction and Simes, 1986).
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The results demonstrate excellent test-retest repeatability 
of [18F]ASEM PET of >90%. In the population of 21 healthy non-
smoking volunteers, when we plotted tracer distribution vol-
ume VT against age, we observed an increase with of VT with age. 
While our smaller sample and lack of a wide age distribution 
limited our ability to test this relationship formally with regres-
sion analysis, the trends in our data match the findings from a 
larger age range in another set of subjects (Coughlin et al., 2018, 
which had only 2 subjects in common that we provided to the 
Coughlin paper previously). The preliminary findings of values 
of VT vs age are shown in supplementary Figure D.
We were unable to determine sex differences because of the 
different age ranges. Of the 8 women, none of them showed a 
specific effect of menstrual cycle on estimates of VT.
Receptor BPND 
Estimates of Bmax are based on determination of BPND (Gjedde 
et al., 2005). Importantly, for the first time, we present evidence 
that competitor occupancy, apparent KI, and Bmax of human α7-
nAChR can be measured, based on the assumptions presented. 
We determined regional estimates of [18F] ASEM binding as the 
first step towards complete receptor quantification. In addition 
to regional values of VT, the receptor quantification required 
knowledge of the magnitude of VT of the tracer in a region of 
brain tissue with no specific binding. Previously, no such refer-
ence volume has been identified for this tracer with prevalent 
binding in cerebral cortex. As the first PET study with blockade 
of α7-nAChR in human brain in vivo, this study took advantage 
of the original development of the well-documented partial 
agonist DMXB-A at the University of Florida (Kem, 2000; Kem 
et al., 2004) and the subsequent successful testing in patients 
with schizophrenia at the University of Colorado (Olincy et al., 
2006; Freedman, 2014).
Receptor Occupancy
Recent studies of mouse and baboon brains revealed significant 
blockade of the α7-nAChR by the high-affinity partial α7-nAChR 
agonists SSR180711 and DMXB-A in vivo (Horti et  al., 2014a; 
Wong et al., 2014), but effective inhibition or competition has not 
yet been confirmed in humans. As a candidate drug, DMXB-A 
was tested in clinical trials of patients with schizophrenia, 
Alzheimer’s disease, or ADHD (Freedman et al., 2008; Freedman, 
2014), and the drug was used here to test target engagement/
occupancy in vivo at the α7-nAChR and to demonstrate specifi-
city of [18F]ASEM binding to these receptors.
Previously, we demonstrated dose-dependent tracer inhib-
ition in rodents by DMXB-A with cerebellum as reference region 
(appropriate in rodents but not human brain) (Wong et al., 2014). 
Similarly, in the present study, blockade with the highest dose 
of DMXB-A allowed in humans (150 mg orally) exhibited com-
petition with binding of [18F]ASEM. The occupancy of receptors 
by DMXB-A displayed a relatively monotonic relationship with 
plasma levels of DMXB-A.
We used the EIP under the assumption that the apparently 
absent inhibition of receptor binding would be due to factors 
such as change of free fractions of the radioligand in circulation 
or brain tissue or both, with the consequence that the value of VND 
would differ between the baseline (VND (b)) and inhibited (VND (a)) 
states, as reported by Phan et  al. (2017). Using EIP and the 
value of VND(b) of 5.4  mL/cm
3 obtained from moderate block-
ade of the α7-nAChR in baboon brain, reported by Horti et al. 
(2014) as a simple reduction in slope and reanalyzed by the 
standard IP here, we obtained DMXB-A occupancies in the 
human subjects in the range of 17% to 49%. Future studies 
with new α7-nAChR drugs will further test the occupancy and 
the accuracy of the resulting estimates of Bmax and affinity in 
human brain in vivo.
With the assumptions and translation from autopsy pro-
tein and wet tissue-based Bmax of α7-nAChR, we find remarkable 
agreement among the Bmax estimates that we regard as another 
innovative aspect of the present study. As 150 mg is the highest 
single oral dose allowed under the DMXB-A IND based on histor-
ical information, we elected not to test lower doses, because of 
the modest occupancy, compared with occupancy of drugs such 
as antipsychotics, and more recently glycine transporter (GlyT1) 
ligands (Martin-Facklam et al., 2013; Wong et al., 2013). However, 
the dose dependent occupancy with DMXB-A is evidence of spe-
cificity of the radiotracer [18F]ASEM in human brain. The occu-
pancy is further evidence of the potential usefulness of [18F]
ASEM for therapeutic occupancy trials, as these are somewhat 
complicated due to the inverted-U-shaped dose effect of α7-
nAChR partial agonists (Young and Geyer, 2013).
The α7-nAChR receptor has 5 binding sites among the 5 α7 
subunits and is maximally activated when at least 2 binding 
sites are occupied by an agonist. At higher doses, agonists bind 
at up to all 5 binding sites and progressively desensitize the α7. 
Moreover, α7 partial agonist drugs such as DMXB-A and oth-
ers produce their clinical effects at lower concentrations than 
would be expected from in vitro functional experiments where 
peak currents are recorded (Prickaerts et al., 2012; Papke, 2014; 
Preskorn et  al., 2014). The co-agonistic mechanism of in vivo 
action of α7 partial agonist suggests that DMXB-A, at the clinic-
ally effective dose, binds at 1 of 5 binding sites of α7, while brisk 
activation of the receptor will, however, occur upon exposure 
to endogenous ACh. Thus, in vivo, a single molecule of DMXB-A 
plus 1 molecule of ACh are sufficient to trigger the opening of 
the α7-nAChR channel (Williams et  al., 2011; Prickaerts et  al., 
2012; Papke, 2014; Preskorn et  al., 2014). Therefore, in the PET 
occupancy studies with the DMXB-A-treated humans, the bind-
ing of [18F]ASEM is expected to be inhibited by as little as 20% to 
40% (one-fifth to two-fifths) instead of 100%. This co-agonistic 
mechanism agrees reasonably with our PET [18F]ASEM inhibition 
by DMXB-A in humans at 17% to 49% with a maximum clinical 
dose of DMXB-A (150 mg). Full blocking of [18F]ASEM with α7 ago-
nists occurs at higher doses, as observed in mice with 20 mg/kg 
DMXB-A (Horti et al., 2014a; Wong et al., 2014) and in baboons 
administered 5 mg/kg of the more highly potent SSR180711 that 
is unavailable in the United States for human use (Horti et al., 
2014).
Receptor Density and Tracer Affinity
The use of the EIP with the DMXB-A inhibition and the use of 
the estimate of VND from baboon brain (Horti et al., 2014) yielded 
the binding potentials necessary to estimate the average values 
across all binding regions of Bmax (0.67–0.82  nM) and KI (range 
170–385) in human brain. While the value of VND in humans cur-
rently is unknown, the baboon value of 5.4 mL/cm3 estimated 
here with SEM of 2.7  mL/cm3 corresponded to ranges of Bmax 
estimates of 0.75 (range 0.38–1.83) nM and DMXB-A KI estimates 
of 138 to 363 nM. These values agree favorably with estimates 
postmortem of 0.28  nM Bmax for human cerebral cortex with 
α-[125I]bungarotoxin (Davies and Feisullin, 1981) and cortical Bmax 
values of 0.7 nM in patients with schizophrenia compared with 
1.5 nM in healthy control subjects (Marutle et al., 2001), assum-
ing 10% mg protein converted to wet weight.
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Schizophrenia
In the feasibility study of 6 patients with schizophrenia, we 
observed reductions of VT in 5 of the 6 subjects. The finding 
of significant reduction of regional distribution in 5 of 6 sub-
jects in 2 of 3 regions after outlier exclusion of a single subject 
agreed with previous findings postmortem. However, in the 
present study, the difference between controls and patients is 
lower than observed postmortem. This finding could be due to 
a number of factors, such as tracer differences ([18F]-ASEM vs 
[125I]-BTX), in vivo vs in vitro tests, and the heterogeneity of the 
patient population.
Limitations
Antipsychotic Medication
Neuroreceptor studies of patients with schizophrenia in the 
drug free or naïve state are increasingly logistically challeng-
ing, although such studies have been completed in limited 
populations (Farde et al., 1986; Wong et al., 1986). In the present 
limited population, patients with schizophrenia were tested 
while on stable medication for more than 3 weeks with antip-
sychotics that are held to have only negligible effect on binding 
to α7 nAchR and to be nonexclusionary in therapeutic studies 
of partial agonists such as DMXB-A, e.g., clozapine (which was 
exclusionary). Several precautions were taken to reduce the pos-
sibility of confounding antipsychotic action in the quantifica-
tion of binding to α7nAchR. First, the majority of the patients 
were treated with risperidone and haloperidol, which unlike 
clozapine fail to normalize the P50 abnormality (Adler et  al., 
1998). Second, a rodent biodistribution study found no signifi-
cant effects on [18F]ASEM binding. Finally, although only 1 sub-
ject was studied off medications, the repeated PET test on and 
off chronic risperidone was suggestive of the conclusion that 
this commonly used antipsychotic is unlikely to confound the 
estimates of the VT values for α7 nAChR.
Effects of Smoking
All 21 control subjects and 5 of the 6 patients with schizophrenia 
were nonsmokers. We considered comparing smokers with non-
smokers but did not recruit a sufficient number of healthy volun-
teers with clinically verified smoking status. By design therefore 
we studied only nonsmoking control subjects in the current 
protocol of test-retest and occupancy studies and comparison 
with the feasibility study of 6 patients with schizophrenia.
Despite the relatively high prevalence of smoking in patients 
with schizophrenia, only 1 of the subjects randomly recruited 
with schizophrenia smoked (20 cigarettes/d). Most subjects were 
younger (<35 years old), which may be a contributing factor, as it 
has been reported that younger subjects are less likely to smoke 
(for an example of this trend, see https://www.hhs.gov/ash/oah/
adolescent-development/substance-use/drugs/tobacco/trends/
index.html). The patient that happened to be a regular smoker 
also happened to be the oldest of the patients at 31 y (age range 
of patients 20–31 y, mean 24.9 y). The VT values did not differ 
significantly for the smoking subject compared with the other 
patients with schizophrenia with low value of VT.
Furthermore, on the day of PET, all control subjects and 
patients with schizophrenia had CO values <4 PPM, indicating 
successful abstinence (regardless of their self-reports) and likely 
longer than 12 h, reducing the acute effects of nicotine, if any, on 
the PET measure of the tracer VT.
As a  future direction, we specifically will recruit partici-
pants for inclusion into cohorts of smokers and nonsmokers of 
both healthy controls and patients with schizophrenia to fur-
ther explore smoking effects. The assignments will be verified 
by smoking history, urine cotinine levels, CO breath measures, 
and assessments of extent of nicotine use and dependence (e.g., 
Fagerstrom, MINI nicotine use, Minnesota Nicotine Scale, and 
Michigan Nicotine Reinforcement Questionnaire). With a larger 
sample, the schizophrenia group is likely to comprise more 
smokers, particularly among older patients.
Age and Sex Differences
In the group of 21 subjects in the age range of 18 to 50 y, males 
and females were not distributed uniformly, ruling out formal 
determination of sex differences as functions of normal aging. 
Also, the small number of 5 subjects with DMXB-A occupancy 
nonetheless yielded a reasonable range of DMXB-A human 
plasma concentrations, presumably due to individual variability 
in oral absorption and metabolism of the inhibitor.
Schizophrenia
In this feasiblity study, the small number of patients with 
schizophrenia is a statistical limitation. In 5 of the 6 subjects, 
estimates of VT in 2 of 3 regions compared with age-matched 
control subjects, as well as a formal outlier analysis, suggested 
that the high values of VT in one subject may have had other 
causes leading to the elevation. Thus, expansion of the number 
of patients with schizophrenia and detailed documentation of 
the clinical and neuropsychological features of the patients will 
help expand the findings of factors that influence the hetero-
geneity of α7nAchR findings.
Conclusions
Here, we confirmed the test-retest reliability of tracer binding in 
healthy human brains, and we demonstrated for the first-time 
specificity of competition from the partial agonist DMXB-A in 
normal healthy volunteers, as previously reported in preclinical 
imaging studies. The novel first time presentation of in vivo Bmax 
measures agreed favorably with published human postmortem 
values. The effects of antipsychotics in our schizophrenia vol-
unteers may not be a major confound based on our preliminary 
mice and literature and one subject on and off risperidone. The 
preliminary findings in patients with schizophrenia suggest the 
feasibility of imaging this important disorder and generally con-
sistent with previous reports of human brains postmortem, but 
clearly larger samples with a spectrum of clinical severity and 
comparisons with full cognitive and neuropsychological tests 
are needed.
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